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Abstract
Background: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) or chronic fatigue syndrome (CFS) has
been used to name a range of chronic conditions characterized by extreme fatigue and other disabling symptoms.
Attempts to estimate the burden of disease have been limited by selection bias, and by lack of diagnostic
biomarkers and of agreed reproducible case definitions. We estimated the prevalence and incidence of ME/CFS in
three regions in England, and discussed the implications of frequency statistics and the use of different case
definitions for health and social care planning and for research.
Methods: We compared the clinical presentation, prevalence and incidence of ME/CFS based on a sample of
143,000 individuals aged 18 to 64 years, covered by primary care services in three regions of England. Case
ascertainment involved: 1) electronic search for chronic fatigue cases; 2) direct questioning of general practitioners
(GPs) on cases not previously identified by the search; and 3) clinical review of identified cases according to CDC-
1994, Canadian and Epidemiological Case (ECD) Definitions. This enabled the identification of cases with high
validity.
Results: The estimated minimum prevalence rate of ME/CFS was 0.2% for cases meeting any of the study case
definitions, 0.19% for the CDC-1994 definition, 0.11% for the Canadian definition and 0.03% for the ECD. The overall
estimated minimal yearly incidence was 0.015%. The highest rates were found in London and the lowest in East
Yorkshire. All but one of the cases conforming to the Canadian criteria also met the CDC-1994 criteria, however
presented higher prevalence and severity of symptoms.
Conclusions: ME/CFS is not uncommon in England and represents a significant burden to patients and society.
The number of people with chronic fatigue who do not meet specific criteria for ME/CFS is higher still. Both
groups have high levels of need for service provision, including health and social care. We suggest combining the
use of both the CDC-1994 and Canadian criteria for ascertainment of ME/CFS cases, alongside careful clinical
phenotyping of study participants. This combination if used systematically will enable international comparisons,
minimization of bias, and the identification and investigation of distinct sub-groups of patients with possibly
distinct aetiologies and pathophysiologies, standing a better chance of translation into effective specific treatments.
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Despite being described more than five decades ago
[1,2], myalgic encephalomyelitis/chronic fatigue syn-
drome (ME/CFS) remains controversial and poorly
understood by health professionals [3] and the wider
public. ME/CFS diagnosis is still one of exclusion and is
mainly based on the presence of persistent or recurrent
chronic fatigue associated with a range of symptoms,
which often fluctuate, sometimes even over short peri-
ods of time. A number of case definitions and clinical
labels, with varying degrees of sensitivity and specificity
[4,5] have been used to characterize the cases [2,6-13].
Primary care practitioners have used diverse case defi-
nitions and diagnostic labels to describe their chronically
fatigued patients, for example CFS, ME, post viral fati-
gue syndrome, fibromyalgia, asthenia, and post-viral
debility [14]. Terminological variations and inconsisten-
cies in how definitions and labels are used have ren-
dered studies on the occurrence and distribution of ME/
CFS in populations difficult to compare, unless robust
and consistent methods, including case definitions that
can discriminate ME/CFS cases from cases of chroni-
cally fatigued non-ME/CFS, are applied. Precise statistics
about the burden of the disease, including its spatial dis-
tribution and level of severity, are crucial for adequate
planning of health and social services and of research.
Our approach to the selection of case definitions applied
in the study reported in this paper is described in the
Methods section below. While both ME/CFS and
chronically fatigued non-ME/CFS patients have debili-
tating conditions [4,5] and need high levels of health
care and social support, those with ME/CFS may have
distinct needs in relation to diagnosis and therapeutic
options, as they are likely to constitute a distinctive
nosological condition, albeit that the pathophysiology is
still unclear. These are still largely unmet for reasons
likely to be related to their perceived lack of recognition
as having a legitimate condition. Moreover, the absence
of a definitive diagnosis may lead to their receiving
inadequate care and support [15].
This paper describes the prevalence rates and annual
incidence risk of ME/CFS in primary care in parts of
England, based on samples from London, East Anglia
and East Yorkshire, and discusses the implications of
the frequency statistics and the use of different case
definitions for planning health and social care and
research.
Methods
The study was part of the ME/CFS Observatory, a colla-
borative research program that encompasses quantitative
and qualitative studies and the piloting of an ME/CFS
specific disease register [16,17]. It was carried out fol-
lowing approval from the Multi-Centre Research Ethics
Committee in London (London-MREC - 06/MRE/02/
57), the London School of Hygiene and Tropical Medi-
cine Ethics Committee and the local NHS Research
Governance Units in London, East Anglia and East
Yorkshire.
The study comprised two cross-sectional surveys
twelve months apart, involving a population of 143,000
people between 18 to 64 years of age from 29 general
practices in three regions of the country, carried out
between 2007 and 2010. Five of the general practices
were located in parts of London, five in East Anglia and
19 in East Yorkshire. Some patients were also recruited
from a specialist ME/CFS service in East Anglia, run by
GPs with special interest in ME/CFS, and data from
these patients are included in some of the analyses, but
excluding all analyses leading to prevalence and inci-
dence estimates. The inclusion of 45 cases from the spe-
cialist clinic aimed to add cases, and thus power to
some of the epidemiological analyses. Identical proce-
dures for diagnosis were used in GP practices and spe-
cialist clinics, except that the latter contains a further
level of diagnostic confirmation, as cases are referred by
GPs and receive diagnostic confirmation by another
health professional (and we compared the results with
and without these patients). The study areas were
selected within the geographical areas of the participat-
ing institutions, and to capture populations with large
representation from ethnic minorities (London), with
Caucasians over-represented in Norfolk and East York-
shire, both of which had proportionately large rural
populations. We were careful to choose practices with
GPs with experience in diagnosing ME/CFS. The effect
of this approach on representativeness of cases was
judged to be justified, otherwise we would have severely
under-estimated the true disease occurrence, as GPs
w i t h o u ta ni n t e r e s ti nM E / C F Sw o u l dm o r eo f t e nf a i l
diagnose it. This resulted in an imbalance in numbers of
GP practices in the three -regions, with East Yorkshire
over-represented. The sample size was calculated (using
EPI-INFO version 3.7 software) to detect a prevalence
of ME/CFS of 0.5% with a confidence level of 95% and
precision of 0.4%. Lower precision would be achievable
for population subgroups defined by geographic location
and gender, and for incidence risk estimation.
Recruitment of patients followed a staged approach for
the identification of cases (Figure 1), starting with a
search of general practitioners’ (GP) electronic data-
bases. The participating general practices identified and
selected all 18-to-64-year-old patients whose medical
records contained any of the following diagnoses: CFS,
M E ,p o s t - v i r a la s t h e n i cs y n d r o m e( P V A S ) ,f a t i g u es y n -
drome (FS), fibromyalgia (FMS), post-infectious ence-
phalitis (PIE), and any other codes offered by the
participating GPs to denote cases of ME/CFS. The use
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tinct case definitions, but on diagnostic terms occurring
in the READ clinical lexicon, which is the basis for clini-
cal coding and classification in GP computer systems in
the UK. The READ lexicon does not contain definitions,
but simply reflects practices by individual GPs in rela-
tion to naming cases with similar clinical pictures [18].
The terms listed above we refer to as primary diagnoses.
The GPs were asked to review all cases identified with
primary diagnoses, using the study case definitions,
 
Refusals 
Participating GPs 
Research Team 
Data collection 
Questionnaires sent to consenting individuals, by post, containing questions related to symptoms 
characterization, onset, duration, relation to activities, and co-morbid conditions 
Data entry 
Completed questionnaires entered onto 
secured electronic database  
Non-cases 
Individuals with unexplained chronic 
fatigue who did not comply with at least 
one of the study case definitions 
n= 122 (P) + 4 (NC) 
Case ascertainment 
Ascertainment of cases according to the 
study case definitions, based on an in-built 
electronic algorithm  
Data quality check 
Completed questionnaires reviewed by 
central research team, for consistency and 
missing data 
Cases of ME/CFS 
Individuals complying with at least one of 
the study case definitions.  
n= 265 (P) + 13 (NC) 
Identification of possible participants 
Patients (18 -64 year-olds) identified with a primary 
diagnosis
1, by electronic database search  
n= 573 (prevalent – P) + 36 (new cases – NC) 
Clinical revision 
Exclusion of individuals who were no longer cases 
Exclusion 
 Exclusion of patients with 
explained chronic fatigue 
n= 63 (P) + 7 (NC) 
Invitation to participate in the study 
n= 510 (P) + 29 (NC) 
Subjects’ consent 
Informed consent given 
n=387 (P) + 17(NC) 
No answer to invitation letter 
2
nd attempt by post 
3
rd attempt by phone  
Refusals/missing  
n=123 (P) + 12 (NC) 
Figure 1 Flowchart of recruitment and ascertainment of cases. Note:
1 Chronic fatigue syndrome (CFS), myalgic enchephalopathy (ME), post
viral asthenic syndrome (PVAS), fatigue syndrome (FS), fibromyalgia (FMS), post-infectious encephalitis (PIE), and any other codes offered by the
GPs to denote cases of ME/CFS.
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months, and to exclude those they no longer considered
as cases, either because of clinical improvement or the
finding of any other clinical condition explaining their
symptoms. In addition they were asked to identify by
recall any further cases that might not have been picked
up by the electronic searches.
The GPs then sent a letter to the selected patients
inviting them to participate in the study. Potential parti-
cipants received an information pack containing the
invitation letter from their GP, an information sheet
about the study, consent forms and a research study
questionnaire. The questionnaire developed by the
authors was a symptom checklist containing questions
on symptoms and functional capacity enabling case
ascertainment and classification according to one or
more of the diagnostic criteria used in the study. Those
with ME/CFS diagnosed by the GPs but who did not
meet any of the study criteria were considered as non-
cases for the purpose of this study.
For someone to be confirmed as a case of ME/CFS for
the purpose of the study, compliance with any of three
distinct case definitions was required. These were the
Centers for Disease Control (CDC) definition of 1994,
referred to here as the CDC-1994 criteria [9]; the clini-
cal working case definition established in Canada by an
Expert Medical Consensus Panel, known as the Cana-
dian criteria [7], which appears more stringent than the
CDC-1994 definition, and to define as having ME/CFS a
more unequivocally ill group of patients. We also used a
case definition developed by two of the authors so as to
investigate its usefulness for epidemiological research,
and to attempt to validate it. It is referred to in this
report as the Epidemiological Case Definition - ECD
[11]. This was developed by requesting GPs to complete
a symptom checklist with respect to all patients on their
practice lists with unexplained chronic fatigue. The
symptom checklist comprised all the clinical features in
the various case definitions of ME/CFS, including the
CDC-1994 and Canadian definitions. Patients were then
assigned, following perusal of the completed checklists
by an expert reference group, to disease or non-disease
groups. Discriminant analysis was then applied to iden-
tify which symptoms were most effective in assigning
cases accurately to the disease or non-disease groups.
The symptoms thus identified became de facto the epi-
demiological case definition.
Compliance with the above case definitions was ascer-
tained by use of a computerized algorithm which
mapped symptom profiles onto the case definitions.
Estimates of the prevalence of ME/CFS were then made
on the basis of cases identified in this way, using the
number of patients in the practice lists as denominators.
The choice of different diagnostic criteria was intended
to enable international comparisons, and to examine
distinct patterns of symptoms and severity. The CDC-
1994 and Canadian criteria in particular were chosen as
they have been widely used worldwide.
For their further characterization, all participants were
also asked to complete a visual analogue pain scale [19]
and a scoring instrument to access the severity of the
fatigue symptom based on the Karnofsky rating scale
[20]. For the pain scale, the respondents marked their
level of pain on a 10 cm line ranging from 0 = no pain
to 10 = pain as bad as possible, the measured points in
the line represented the pain scores (as a visual analo-
gue). The severity of fatigue was assessed through a
scale ranging from 0 - no symptoms with exercise, nor-
mal overall activity to 100 - severe symptoms on a con-
tinuous basis, bed ridden constantly, unable to care for
self.
After one year (study phase 2), a new electronic search
was carried out in the same GP practices to identify any
patients with a new diagnosis of ME/CFS since first
recruitment, and to enable the estimation of annual inci-
dence risks. Procedures similar to those described above
were followed to identify and contact patients and to
confirm diagnosis.
We used the software Stata/IC 11.1 for Windows to
undertake the analysis, and tested statistical significance
with Chi-squared or Fisher’s exact tests for comparing
categorical variables [21]. Continuous variables were
compared using the Studentt - t e s to rW i l c o x o nr a n k
sum test [21], where appropriate. Crude annual inci-
dence risks and prevalence rates were calculated with
t h en u m b e ro fp e o p l ea g e d1 8t o6 4y e a r sr e g i s t e r e d
with each of the general practices as the denominators.
On the basis of these, estimates were made for adjusted
regional incidence risks and prevalence rates (and 95%
confidence intervals) according to each and any of the
case study definitions, using the direct standardization
method [21]. Population estimates for England for mid-
2008 (Office for National Statistics) were used as the
reference population [22]. The age standardised inci-
dence risks and prevalence rates were then adjusted by
response rate in each region for both genders, using the
assumption that the occurrence of ME/CFS did not dif-
fer between respondents and non-respondents.
We compared the clinical presentation (report of
symptoms) of patients meeting each study case defini-
tion and non-cases, that is the chronically fatigued
patients recruited by GPs that did not conform to any
of the adopted ME/CFS diagnostic criteria. To remove
duplications when comparing the proportion of the var-
ious symptoms in patients meeting different case defini-
tions, we re-grouped casesi n t ot w og r o u p s ,t h o s e
conforming both to CDC-1994 and Canadian criteria
(the Canadian group), and those conforming to CDC-
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excluded from both groups of patients. This decision
was based on the observation that nearly all patients
meeting the Canadian criteria also met the CDC-1994
criteria.
Results
Characterization of study population
Our sample population was selected from three areas,
which were quite distinct, but which covered a broad
range of characteristics. These included East Anglia, a
largely rural area with numerous small to medium-sized
market towns and few large population centres; East
Yorkshire, with one large city manifesting many of the
features of industrial decline and inner city deprivation
and a large rural hinterland; and London, with a large
non-indigenous and highly mobile population, and
marked economic polarization, with very affluent and
significantly deprived populations living in close proxi-
mity [23]. The practices in London come from areas
where the proportion of people from Black and Ethnic
Minorities (BEM) is around 40%, with up to a third
born outside the UK, large numbers of whom were
f r o ms o u t hA s i aa n ds u b - S a h a r a nA f r i c a[ 2 4 ] .T h ep r o -
portion of individuals under five years of age was in
most places between 6% and 6.5%, while the proportion
of those aged over 65 years varied between 7% and 15%.
Between 20% and 25% of the adults had no formal qua-
lifications [23].
By contrast, the practices in Norfolk were from an
area where the proportion of people from BEM is less
than 3%, and less than 5% were born outside the UK
[24]. The proportion of individuals under five years of
age was 5%, and of those over 65 was 20%; 32% of the
adult population had no formal qualifications [23]. East
Yorkshire has a non-white population of 7%, with 19%
over the age of 65 years. This region tended to have
lower life expectancy and educational achievement than
the other two [23].
We covered populations ranging from some of the
poorest in the country to some of the most affluent. For
example, central Hull, in East Yorkshire, has the 10
th
worse Index of Multiple Deprivation (IMD) in England
(out of 152 areas), while others in London have IMDs
ranking from 19
th to 118
th, and Norfolk ranks 108
th in
the country. In contrast, rural areas in East Yorkshire
are relatively well-off with mean IMD rank of 135
th [25].
Some demographic characteristics of the study popula-
tion are presented in Table 1.
Baseline recruitment
From the 573 patients identified as having any primary
diagnoses (in their medical records), 63 (11%) were
excluded as they no longer had chronic fatigue at the
time of the search, or had been diagnosed with other
conditions explaining their symptoms, such as hypothyr-
oidism, hyperparathyroidism, hydrocephaly, cancer, psy-
chiatric conditions, Crohn’s disease and rheumatoid
arthritis. The proportion of individuals included with
primary diagnoses was evenly distributed among the
three geographical regions: 34.1% from London, 32.1%
from East Anglia and 33.7% from East Yorkshire. More
than 70% (394/510) were women. The median age was
49.3 years (interquartile range (IR) = 40.7 to 56.1) for all
cases. For men it was 49.1 years (IR = 39.7 to 55.4) and
for women 47.5 years (IR = 38.5 to 55.4); p = 0.56). The
response rate was 75.9% (387/510).
Second recruitment (12 months following initial
recruitment)
One year after the baseline recruitment, an additional 36
new cases were identified from the GP records. Seven
Table 1 Demographic data on GP practices and study population in the three studied regions
Region Regional Population
a GP practices’
population
b
GP Practices
in the
region
c
(n)
GPs in
the
region
c
(n)
Participating
practices
(n) (%)
Participating
GPs
(n) (%)
Total
(n)
18-64
year-olds
(%)
Gender Ethnicity
Male
(%)
Female
(%)
White
(%)
BEM
d
(%)
18-64
year-olds
(n)
18-64
year-olds
(%)
East
Yorkshire
597,200 60.4 48.8 51.2 98.3 1.7 82,080 22.8 105 375 19 18.1 162 43.2
London
e 508,400 65.1 48.6 51.7 61.1 38.9 33,047 10 86 414 5 5.8 31 7.5
East
Anglia
964,800 59.3 48.6 51.4 98.5 1.5 28,026 4.9 136 672 5 3.7 26 3.9
aEstimated population mid-2008. Source: Office for National Statistics - http://www.statistics.gov.uk/statbase/product.asp?vlnk = 15106;
bSource: http://www.nhs.
uk/Services/Pages/AcuteTrustList.aspx?trustType=PrimaryCare;
cSource: https://www.nhs.uk/servicedirectories/Pages/ServiceSearch.aspx;
dBEM: Black and Ethnic
Minorities;
eHarrow and Southwark Primary Care Trust areas.
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Page 5 of 12were excluded by the GPs, and 29 were invited to take
part in the study. Seventeen of them responded
(response rate of 58.6%), of whom 13 (76.5%) met at
least one of the study case definitions for ME/CFS.
ME/CFS caseness for prevalent and incident cases
Two hundred and seventy eight of the recruited patients
(68.8%) met at least one of the ME/CFS study case defi-
nitions, while 122 were considered non-cases. Of the
included cases, 95.3% (265) were prevalent and 4.7%
(13) incident cases, that is identified at the baseline and
at the 12 months recruitment, respectively. We observed
that GPs’ diagnoses of CFS and FMS were more likely
to comply with the study case definitions (positive pre-
dictive values (PPV) = 72.3% and 71.1%, respectively),
than less specific labels such as fatigue syndrome. All
labels referring to post-viral syndromes showed PPV
lower than 50% (Table 2).
The majority of ME/CFS cases complied with the
CDC-1994 criteria (97.1%), 52.5% conformed to the
Canadian criteria and 16.9% to the ECD. However, there
was a considerable overlap among case definitions, as
shown in Table 3. For example, 270 patients met the
CDC-1994 criteria. Of these, 127 also met the Canadian
criteria, while 18 met both the Canadian and ECD defi-
nitions. A total of 103 fulfilled the CDC-1994 definition
but neither of the others.
Prevalence estimates
When the three case definitions used in the study were
considered concurrently, we found an overall ME/CFS
prevalence rate of 0.20%, after correction for non-
response. The rate varied slightly among and within the
regions, with London presenting the highest rate of
0.31% (ranging from 0.12 to 0.50%), followed by East
Anglia of 0.25% (ranging from 0.15 to 0.33%), and East
Yorkshire at 0.14% (ranging from 0.03 to 0.32%). These
rates also varied by gender, with the overall and within
the regions prevalence rates consistently higher in
w o m e nt h a ni nm e n( T a b l e4 ) .T h eh i g h e s tp r e v a l e n c e
rate was found among women in London (0.48%); while
in men, the highest prevalence rate was found in East
Anglia (0.15%). The prevalence rate of cases meeting the
CDC-1994 definition was 0.19%, of cases meeting the
Canadian definition 0.11%, and of cases meeting the
ECD 0.03%.
One year incidence risk
The overall risk was 0.15‰. It was 0.33‰ (range 0 to
1.07‰) in London, 0.24‰ (range 0.20 to 0.26‰) in East
Anglia, and 0.02‰ (range 0.13 to 0.35‰)i nE a s tY o r k -
shire. The overall risk was higher in women than in
men (respectively, 0.41‰ and 0.06‰). Annual incidence
risks also differed among and within the regions (Table
5).
Characterization of prevalent cases
One hundred and seventy five prevalent case individuals
completed the second questionnaire (response rate =
66%). More than half of these cases were between 45
and 65 years of age (66.9%). Men were slightly older
than women (median age 53.2 (IR = 47.5-60.2) and 49.6
(IR = 40.4 -56.5), respectively (P = 0.05). Only 7.5% (13/
174) considered themselves as not White British, and
almost half completed secondary education (91/172).
Overall, 74.6% (129/173) were married or living with a
partner.
Symptoms and case definitions
The onset of symptoms was reported to range from 6
months to 27 years before recruitment to the study. The
median time from the start of symptoms was 8 years (IR
= 4 to 15). One hundred and thirty-three (76%) respon-
dents recognized triggering factors for their symptoms,
such as episodes of infection (57.9%, of which 74% were
reported as viral infections), psychological stress (24.8%),
trauma or surgery (11.3%), and other factors (6.0%). We
found no differences in the distribution of triggering fac-
tors between the cases in conformity with the Canadian/
CDC-1994 criteria and those in conformity with the
CDC-1994 criteria only.
The frequency of symptoms (assessed in all 265 preva-
lent cases) varied according to case definitions used.
However, unrefreshing sleep appeared across the case
Table 2 Positive predictive value of primary diagnoses given by GPs for ME/CFS
GP’s primary diagnoses ME/CFS Not ME/CFS Positive Predictive Value (%)
n% n % Total
Any primary diagnosis 278 100.0 126 100.0 404 68.8
Chronic fatigue syndrome 175 62.9 67 53.2 242 72.3
Fibromyalgia syndrome 81 29.1 33 26.2 114 71.1
Fatigue syndrome 3 1.1 2 1.6 5 60.0
Post-viral asthenic syndrome 16 5.8 18 14.3 34 47.1
Other
a 3 1.1 6 4.8 9 33.3
aThat is, post-viral debility, post-viral syndrome, post-viral fatigue
Nacul et al. BMC Medicine 2011, 9:91
http://www.biomedcentral.com/1741-7015/9/91
Page 6 of 12definitions as the most frequent (proportions ranged
from 97% to 100%), followed by memory and concentra-
tion problems (from 95% to 98%), joint (76% to 91%)
and muscle pain (74% to 95%). In general, the frequency
of each of the symptoms investigated was highest in
those complying with the Canadian criteria, and lowest
in those conforming to the ECD (Table 6). Table 7
shows that the proportion of patients reporting sleep
dysfunction and symptoms related to neurological/cog-
nitive, immunological and psychological functions was
significantly higher in the group conforming to the
Canadian criteria than in the group conforming only to
the CDC-1994 criteria. The proportions were similar
only in relation to pain in two or more joints without
inflammatory signs (P = 0.29). Most, but not all of the
reported symptoms were proportionally higher in the
group conforming to the CDC-1994 criteria only (non-
Canadian) than in the non-cases group. In the group
complying with the Canadian criteria all the symptoms
were proportionally higher than in the non-cases, these
differences being statistically significant. Comparisons
between the groups conforming to the Canadian criteria
and CDC-1994 criteria only (non-Canadian) have shown
that all the reported symptoms were higher in the Cana-
dian group (P = 0.000, apart for migraine where P =
0.002, these P values are not presented in Table 7).
Fatigue was predominantly reported as moderate to
severe, with median of 60 (IR = 50 to 70). There were
no differences in fatigue scores between genders (P =
0.99). Pain was also mainly scored as moderate (median
= 6; IR 3.5 to 7). Again there was no statistical differ-
ence in pain scores between genders (P = 0.06). Signifi-
cant differences were observed in fatigue scores between
the Canadian and CDC-1994 groups, those in the for-
mer group having a median fatigue score of 70 (IR = 50
to 75), while in the CDC-1994 group the median fatigue
score was 50 (IR = 45 to 70), P = 0.000.
The Canadian group had higher pain scores than the
CDC-1994 group (respective medians were 6 (IR = 5 to
8) and 5 (IR = 3 to 7); P = 0.003). The group classified
as non-cases had lower fatigue and pain scores (respec-
tive medians, 40 (IR = 40 to 60) and 2 (IR = 0 to 6) and
in relation to the CDC-1994 group (P < 0.001).
Discussion
This study investigated the epidemiology of ME/CFS in
primary care in parts of East Anglia, London and East
Yorkshire in England, using three case definitions. Pri-
mary care services in the UK can be used as an ade-
quate setting for population based studies, due to their
virtually universal population coverage [26-28]. While
we do not claim to have systematically sampled commu-
nities to ensure UK representativeness, these three
regions between them manifest most of the community
types found in England [22,23,25].
The overall prevalence rate, for all case definitions
combined, was 0.2%. Nevertheless, the population preva-
lence rate may be higher than that, as some people may
not consult their GPs, or do not receive a diagnosis.
Most cases conformed to the CDC-1994 definition, for
which the prevalence was 0.19%, while about half (pre-
valence 0.11%) conformed to the Canadian definition.
All but one of the cases who met the Canadian defini-
tion also met the CDC-1994 criteria, which suggests
Table 3 Distribution of ME/CFS cases (prevalent and
incident) according to the study case definitions
ME/CFS Diagnostic Criteria n %
Any ME/CFS diagnostic
criteria
278 100.0
CDC - 1994 270 97.1
CDC - 1994 only
a 103 37.1
Canadian 146 52.5
Canadian only
a 1 0.4
ECD 47 16.9
ECD only
a 7 2.5
Overlap of case definitions CDC - 1994 and Canadian 127 45.7
CDC - 1994, Canadian and
ECD
18 6.5
CDC - 1994 and ECD 22 7.9
aNon compliant with other definitions
Table 4 Crude, directly standardised and adjusted prevalence rates of ME/CFS
GP Practices ME/CFS cases
(n)
Population
18 - 64 years old
Crude
prevalence rates
(%)
Directly standardised prevalence rates
a
(%)
Prevalence rates
adjusted by response
rates
b
(%)
T T T M F T (95% CI) M (95% CI) F (95% CI) T M F
All practices 219 143,153 0.15 0.06 0.25 0.15 0.13 - 0.17 0.07 0.05 - 0.09 0.23 0.20 - 0.26 0.20 0.09 0.30
London 32 33,047 0.10 0.02 0.18 0.10 0.07 - 0.14 0.02 0.01 - 0.06 0.18 0.12 - 0.26 0.31 0.13 0.48
East Anglia 71 28,026 0.25 0.10 0.41 0.24 0.19 - 0.30 0.11 0.06 - 0.19 0.36 0.27 - 0.46 0.25 0.15 0.36
East Yorkshire 116 82,080 0.14 0.06 0.23 0.14 0.11 - 0.17 0.06 0.04 - 0.10 0.20 0.16 - 0.25 0.14 0.05 0.20
aReference population: England mid-2008 population (source: Office for National Statistics - http://www.statistics.gov.uk/statbase/product.asp?vlnk = 15106);
bAssumption: The respondents and non-respondents have proportionally the same number of ME/CFS cases; T, Total; M, male; F, female; based on 29 GP clinics
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Page 7 of 12that the former may represent a particular subgroup of
the latter. Rates according to the ECD were much
lower, suggesting this case definition does not have suf-
ficient diagnostic sensitivity to be useful on its own and
we were therefore unable to validate it. Symptom preva-
lence and severity of cases, as indicated by the pain and
fatigue scales were greater among those conforming to
the Canadian definition than among those who did not,
further enhancing the proposition that these patients
may represent a distinct sub-group among those con-
forming to the CDC-1994 criteria. We have also
compared quality of life of those meeting each of these
case definitions, showing those meeting the Canadian
criteria presented in general poorer results [29].
The overall prevalence rate of 0.2% in this study, or of
0.19% when only CDC-1994 criteria was used, is in the
lower range of the commonly assumed population pre-
valence for the UK [6]. In general, these prevalence
rates are also lower than those previously reported in
primary care settings, such as 2.6% (or 0.5% when psy-
chological morbidity was excluded) from a study carried
out in the UK [30]; and 0.3% to 1.6% shown in studies
Table 5 Crude, directly standardized, and adjusted annual incidence risk of ME/CFS
GP Practices ME/CFS cases (n) Population
18 - 64 years old
Crude annual
incidence risk
(‰)
Standardized annual incidence risk
a (‰) Annual incidence
risk corrected
response rates
b
(‰)
T M F T (95% CI) M (95% CI) F (95% CI) T M F
All practices 13 143,153 0.09 0.04 0.14 0.09 0.05 - 0.15 0.04 0.01 - 0.11 0.13 0.06 - 0.24 0.15 0.06 0.41
London 4 33,047 0.12 0.12 0.13 0.12 0.03 - 0.31 0.10 0.01 - 0.37 0.12 0.01 - 0.43 0.33 0.27 0.31
East Anglia 7 28,026 0.25 0.07 0.44 0.24 0.10 - 0.50 0.07 0 - 0.39 0.38 0.14 - 0.83 0.24 0.07 0.38
East Yorkshire 2 82,080 0.02 0.05 0.02 0 - 0.09 0.05 0.01 - 0.16 0.02 0.05
aReference population: England mid-2008 population (source: Office for National Statistics - http://www.statistics.gov.uk/statbase/product.asp?vlnk = 15106);
bAssumption: The respondents and non-respondents have proportionally the same number of ME/CFS cases; T, Total; M, male; F, female; based on 29 GP clinics.
Table 6 Proportion of reported symptoms in prevalent cases, according to study case definitions
a
Current symptoms All cases
(n = 265)
CDC-1994
(n = 258)
Canadian
(n = 142)
ECD
(n = 43)
Sleep dysfunction Unrefreshing sleep 97.4 97.3 100.0 97.7
Sleep problems 84.9 85.3 94.4 73.0
Neurological/Cognitive manifestations Memory/concentration problems 94.3 95.3 98.0 95.3
Difficulty thinking 81.5 82.0 93.0 74.4
Unexplained muscle weakness 75.1 74.8 88.0 70.0
Light/noise sensitivity 65.7 66.0 82.4 65.1
Difficulty in understanding things 58.1 59.3 76.1 48.8
Confusion or disorientation 54.7 55.0 78.2 44.2
Pain Pain in two or more joints 89.8 91.1 94.4 76.7
Muscle pain 88.9 89.5 95.1 74.4
Muscle discomfort 86.8 88.0 94.4 76.7
Migratory joint pain 75.8 76.4 85.2 53.5
Headaches 64.5 65.5 74.6 60.5
Migraine 28.3 28.3 36.6 25.6
Fatigue/tiredness Fatigue after exercise (> 24 hours) 81.1 80.6 100.0 90.7
Intolerance to exercise 71.7 71.7 85.2 81.4
Malaise after exertion (> 24 hours) 69.1 69.4 85.9 86.0
Psychological Anxiety 70.9 72.5 83.1 39.5
Depression 55.8 56.2 67.6 11.6
Autonomic Sweatiness/cold hands and feet 66.4 67.4 88.0 55.8
Intolerance to be on your feet 61.1 60.8 79.6 55.8
Immunological Sore throat 57.0 56.7 71.8 60.5
Tender glands in the neck/armpits 57.0 57.7 74.6 55.8
Mild fever or chills 52.8 52.7 75.3 46.5
aAll cases complying with each of the definitions are shown in the columns; therefore cases meeting more than one diagnostic criterion appear more than once.
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Page 8 of 12from other countries [31-34], where the CDC-1994 was
used. However, the rate we found is higher than in
other studies based on case reports in the UK [35],
Netherlands [36] and the US [37], which may have been
subject to considerable under-reporting. This prevalence
is similar to that of a seminal community based study
carried out in the US of 0.24% [38], which also used a
robust methodology for case detection. It is slightly
lower than the prevalence found in other community
based studies carried out in the US - 0.42% [39] and in
Nigeria - 0.68% [40], which used similar methodologies.
Studies using more inclusive diagnostic criteria have
yielded prevalence rates up to ten times higher, for
example 2.5% [41], and 1% [42], although potential for
misclassification was higher, with some people with
other fatiguing conditions perhaps being wrongly
included. Bierl et al [41] studied CFS-like syndromes,
and did not include clinical evaluation of patients.
Annual incident risks also varied among and within
the three regions, with an overall risk of 0.15‰.O t h e r
estimates of incidence risk in the UK range from
0.05‰ [14] to 0.37‰ [43], and in the US, 0.18‰ [38].
Although we studied a large population, our findings,
particularly for incidence estimates, should be inter-
preted with caution, due to the small number of cases
and wide confidence intervals. It should also be noted
that these are cases presenting for the first time with
fatigue lasting for at least six months, but possibly fol-
lowing longer preceding periods of illness, due to pos-
sible delays in diagnosis; so, strictly speaking, they are
not incident cases but rather new diagnoses of preva-
lent cases.
Possible reasons for the variation in results between
studies include methodological differences, the exclu-
sion, in our study, of potential cases which did not meet
strict case definitions, under-diagnosis of cases, due to
either lack of disease recognition or misconceptions
about it by health professionals who may not accurately
distinguish ME/CFS from other conditions presenting
with chronic fatigue, or limited access to services.
Table 7 Reported symptoms in ME/CFS prevalent cases according to compliance with Canadian criteria and non-cases
a
Current symptoms Compliance with
Canadian criteria
No
(n = 97)
(%)
Yes
(n = 125)
(%)
Non-case
(n = 122)
(%)
Sleep dysfunction Unrefreshing sleep 93.8
d 100.0
b 63.1
Sleep problems 74.2
b 97.6
d 56.6
Neurological/Cognitive manifestations Memory/concentration problems 89.7
d 97.6
b 54.1
Difficulty thinking 69.1
d 93.6
d 42.6
Unexplained muscle weakness 60.8
c 88.0
d 41.0
Light/noise sensitivity 44.3
b 82.4
d 28.7
Difficulty in understanding things 37.1 77.6
d 32.0
Confusion or disorientation 28.9 78.4
d 26.2
Pain Pain in two or more joints 89.7
d 94.4
d 46.7
Muscle pain 86.6
d 95.2
b 48.4
Muscle discomfort 82.5
d 93.6
b 48.4
Migratory joint pain 71.1
d 87.2
c 40.2
Headaches 51.5
c 76.0
d 32.8
Migraine 15.5 39.2
d 21.3
Fatigue/tiredness Fatigue after exercise (> 24 hours) 52.6
b 100.0
d 37.0
Intolerance to exercise 50.5
b 84.8
d 34.4
Malaise after exertion (> 24 hours) 41.2
b 85.6
d 26.2
Psychological Anxiety 63.0 88.0
d 56.6
Depression 50.5 75.2
d 41.0
Autonomic Sweatiness/cold hands and feet 42.3 88.8
d 38.5
Intolerance to be on your feet 38.1
b 80.8
d 24.6
Immunological Sore throat 37.1 71.2
d 27.0
Tender glands in the neck/armpits 36.1 73.6
d 27.9
Mild fever or chills 23.7 77.6
d 29.5
aAll cases met the CDC-1994 criteria; P-values are shown for comparisons of proportions of symptoms between cases that do not conform to the Canadian
criteria and non-cases; and between cases that conform to Canadian criteria and non-cases. The following symbols show respective P-values:
bP < 0.05;
cP <
0.005;
dP≤0.001; the results comparing ECD with other diagnostic criteria and non-cases are not presented due to small numbers.
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Page 9 of 12Initial GP diagnoses may not always be accurate, and
in our study 11% of those who had been labelled with
one of the primary diagnoses were, on review, found by
their GPs not to be cases, while 24% of GP-diagnosed
cases did not fulfil the study case definitions. GP diag-
noses alone would have generated a prevalence rate of
0.33%, reduced to 0.29% following GP case review. Rea-
sons why GPs might not diagnose ME/CFS cases may
include limited knowledge, or inability or unwillingness
to recognise ME/CFS as a genuine disorder; lack of
access of patients with ME/CFS to their GPs, due to
symptom severity, disillusionment with health services
and low expectations of finding help [15], or cultural
reasons.
We used a robust methodology that involved the
employment of specific diagnostic criteria and rigorously
sequenced filter procedures before confirming cases. To
maximize the identification of cases by GPs, in contrast
to previous studies with primary care patients, we
assessed recruited patients with unexplained chronic
fatigue as well as those who had been labelled with a
range of diagnoses that indicated they might be cases of
ME/CFS. Failure to recognize cases was therefore much
less likely in this study, except perhaps for individuals
from ethnic minorities (see later), particularly as we
worked with selected practices where the GPs were
experienced in diagnosing and less likely to be unsympa-
thetic to ME/CFS. While this may have compromised
the representativeness of the study, we believe that
working with non-engaged health professionals unwill-
ing or unable to diagnose ME/CFS would have been
more disadvantageous.
Despite the lower disease frequency we found com-
pared to some other studies [30-34,39-41], the conse-
quences for health and social care are still considerable,
given the disabling nature of ME/CFS and the high eco-
nomic impact for patients, families and the wider society
[15,44,45]. Moreover the use of a large study population
with a relatively wide geographical distribution enhanced
the study validity.
Our findings of a higher risk of ME/CFS in women
in all regions confirm previous findings [14,39,41,46].
T h em a j o r i t yo fo u rc a s e sw e r er e p o r t e d l yw h i t eB r i t -
ish, which contradicts previous studies that found
similar or even higher prevalence rates in primary
care among non-white groups [32-34,39-41]. It may
be that ME/CFS is less commonly diagnosed among
ethnic minority patients in UK primary care, and this
under-diagnosis may well have contributed to the rela-
tively low prevalence rate. A corollary of this may be
the report by Haines et al o fah i g h e rp r e v a l e n c eo f
severe fatigue in adolescent girls from practices in less
deprived areas, and their suggestion that this could
reflect consulting behaviours [35]. Ethnicity would
not, however, explain the higher rates in London,
which are more likely due to consulting behaviours or
disease recognition in densely populated urban areas.
In addition, it is worth noting the relatively small
number of cases used for inferences, particularly in
London.
The cases recruited for this study had been ill for
varying periods of time, but their fatigue and pain scores
were still moderate to severe in most cases. Pain and
fatigue scores were significantly lower in those chroni-
cally fatigued patients assessed as non-cases than in
those who conformed to CDC-1994 or Canadian cri-
teria, while the highest scores were found among those
meeting this latter case definition. While symptom
reporting is necessarily subjective, there was nevertheless
a consistent and significant variation in the proportions
of symptoms reported in these three groups. This sug-
gests not only a distinction between ME/CFS and other
chronically fatigued cases, but also that there is a dis-
tinction between ME/CFS patients who conform to the
CDC-1994 alone, and those who conform also to the
Canadian criteria. This is in line with the findings of
Jason et al [ 5 ]a n da l s or e f l e c tt h es t r i n g e n c yo ft h e
Canadian definition, in for instance requiring post-exer-
tional fatigue. However, we have not found a higher fre-
quency of GP diagnosis of fibromyalgia in Canadian
positive cases (data not shown, P = 0.9), compared to
CDC 1994. It is unclear whether cases conforming to
t h eC a n a d i a nc r i t e r i ar e p r e s e n tt h es e v e r ee n do fad i s -
ease spectrum, or if they represent a distinct clinical
entity with distinct aetiology.
T h e r ei ss o m ee v i d e n c ew h i c hi n d i c a t e sd i f f e r e n c e s
between ME/CFS and other chronically fatigued cases in
relation to the type and severity of fatigue, somatic
symptoms and biological abnormalities [47]. In the
absence, at present, of reliable biomarkers, the choice of
the most stringent available diagnostic criteria for ME/
CFS for clinical and epidemiological studies is justified
for its ability to distinguish true cases from non-cases,
so as to enable reliable epidemiological inferences and
to ensure study validity [48]. However, the ideal would
be to sub-group research cases according to clinical and
laboratory features [5,47,49-51] that may reflect different
aetiologies and pathophysiologies. Use of the CDC-1994
definition in research is desirable as it has been widely
used and has shown in our study to capture effectively
nearly all cases studied. The improvement in criteria to
incorporate more objective measures of severity and
functional status, as suggested by Reeves [41], is desir-
able, and should reflect the true levels of limitation
experienced by those with ME/CFS, to avoid any artifi-
cial inflation of prevalence statistics [52] and so encou-
rage trivialization of the impact of such a severe disease
on those who live with it.
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The difficulties in measuring the occurrence of ME/CFS
reflect the absence of biomarkers for diagnosis and of
specific, sensitive and reproducible clinical diagnostic
criteria, and the variable perceptions and attitudes of
health professionals about the illness with consequent
inconsistencies in how they establish the diagnosis. We
tried to minimize these difficulties by working with
health professionals with a good understanding of the
disease, by using a robust methodology based on a com-
bination of clinical assessment and patient question-
naires, and by restricting diagnosis confirmation to
those meeting strict study case definitions and appropri-
ate exclusion criteria.
Our study yielded a minimum prevalence in primary
care of 0.2% and a minimum incidence risk of 0.015%.
Due to its disabling and long-term nature, and because
it often affects individuals in the most productive parts
of their lives, this represents a considerable burden to
people affected and to society in general. However, it is
important to recognize that frequency estimates vary
according to how disease status or caseness is defined,
and that the true burden of chronically fatiguing condi-
tions is far higher, with the health needs for those with
non-ME/CFS chronic fatigue also requiring attention.
To achieve optimum care for these heterogeneous
groups of patients, it is very important that specific and
discriminating case definitions are used, and that appro-
priate sub-grouping of cases is applied. This is at least
as important for research, as the standard use of reliable
and specific case definitions is essential to avoid differ-
ential misclassification bias when investigating associa-
tions and making causal inferences. This is vital to
advance the understanding of mechanisms of diseases,
the discovery of biomarkers, and development of specific
treatments for those affected.
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